col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


52 Results       Page 1

 [1] 
Medknow Publications: Indian Journal of Pharmacology
  original article Date Title Authors   All Authors
1 [GO] 2024―Sep―09 Correlation between essential metals and severe acute respiratory syndrome coronavirus 2 infection Anoop Kumar, Manisha Thakur, Mohini Chaurasia, S. J. S. Flora
2 [GO] 2024―May―23 Sharing experience: Hydroxychloroquine in preexposure prophylaxis against COVID-19 Chanda Kulkarni, Adil Sadiq, Arya Gigi, Ambili Devassia, Georgeena George
3 [GO] 2024―May―23 Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19 Yethindra Vityala, Tugolbai Tagaev, Sagynali Mamatov, Ziiabidin Aidarov, Panchadcharam Harinath
4 [GO] 2024―May―23 COVID-19 associated mucormycosis, host-iron assimilation: Probiotics can be a novel therapy Ankit Bhardwaj, Vandana Roy
5 [GO] 2024―May―23 Long coronavirus disease: Consequences of COVID-19 infection and vaccine on cardiovascular diseases ShobanBabu Varthya, Krishna Tiwari, Aswini Saravanan, Abhishek Anil, Surjit Singh
6 [GO] 2024―May―23 Antimicrobial resistance: An unseen threat prowling behind the COVID-19 outbreak Bikash Medhi, Vidya Mahalmani, J Kumaravel, Manav Jain, Ajay Prakash
7 [GO] 2024―May―23 Pattern of clinical research in the era of COVID-19 pandemic: A new learning experience for the present as well as future Bikash Medhi, VidyaM Mahalmani, Ankita Semwal, Harpinder Kaur, Sukhmeet Kaur, Ajay Prakash
8 [GO] 2024―May―23 Successful management of delayed hyaluronidase hypersensitivity after subtenon's anesthesia during the COVID-19 pandemic: A rare case report Bharat Gurnani, Kirandeep Kaur
9 [GO] 2024―May―23 Drug development process and COVID-19 pandemic: Flourishing era of outsourcing KH Reeta, Himika Wasan, Devendra Singh, Pooja Gupta, YogendraKumar Gupta
10 [GO] 2024―May―23 Adverse drug reactions of itolizumab in COVID-19 patient: A case report ManojP Dandekar, Ziauddin Mohammed, Kandi Suryachandra
11 [GO] 2024―May―23 Rhino-orbital-cerebral mucormycosis in COVID-19 patients - Taming the black evil with pharmacological weapons Bharat Gurnani, Kirandeep Kaur
12 [GO] 2024―May―23 Efficacy and safety of inhaled nitric oxide in the treatment of severe/critical COVID-19 patients: A systematic review Bikash Medhi, Ajay Prakash, Sukhmeet Kaur, Charanjeet Kaur, PraisyK Prabha, Anusuya Bhatacharya, Phulen Sarma
13 [GO] 2024―May―23 Intradermal versus intramuscular COVID-19 vaccination aiming at protection for delta variant: cost utility analysis Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
14 [GO] 2024―May―23 Attitude toward COVID-19 vaccination: A cross-sectional study on healthcare professionals Ramachandran Balaraman, Suresh Velumani, Patel Arpita
15 [GO] 2024―May―23 The narrow road to a COVID-19 vaccine BimalKumar Das, SheshPrakash Maurya, Namrata Das, Hitender Gautam, Ravinder Singh
16 [GO] 2024―May―23 Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors Erkan Cure, Adem Kucuk, MedineCumhur Cure
17 [GO] 2024―May―23 Desensitization to liposomal amphotericin B after anaphylaxis in a patient with COVID-19-associated mucormycosis - A case with review of literature Animesh Ray, Satish Swain, Naveet Wig, Anjan Trikha
18 [GO] 2024―May―23 Peptides and peptidomimetics as a therapeutic candidate for the treatment of COVID-19: A brief review Bikash Medhi, J Kumaravel, Harvinder Singh, Sukhmeet Kaur, Ajay Prakash
19 [GO] 2024―May―23 Rhino-orbital-cerebral-mucormycosis in COVID-19: A systematic review Bikash Medhi, Anusuya Bhattacharyya, Phulen Sarma, DibyaJyoti Sharma, KarunaKumar Das, Hardeep Kaur, et al. (+8)
20 [GO] 2024―May―23 Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis Bikash Medhi, Anusuya Bhattacharyya, Subodh Kumar, Phulen Sarma, Hardeep Kaur, Manisha Prajapat, et al. (+7)
21 [GO] 2024―May―23 Role of Vitamin D in COVID-19: Correspondence Pathum Sookaromdee, Viroj Wiwanitkit
22 [GO] 2024―May―23 Decreased mortality among hospitalized coronavirus disease 2019 patients who underwent anticoagulant therapy with heparin Vityala Yethindra, Tugolbai Tagaev
23 [GO] 2024―May―23 In search for a panacea for coronavirus disease-19: Analysis of ongoing clinical trials for the management of coronavirus disease-19 pandemic in India Vandana Roy, Nidhi Maheshwari
24 [GO] 2024―May―23 Virtual screening and molecular dynamics simulation study of approved drugs as a binder to the linoleic acid binding site on spike protein of SARS-CoV-2 and double mutant (E484Q and L452R) Bikash Medhi, Manisha Prajapat, Phulen Sarma, Nishant Shekhar, Arushi Chauhan, Gurjeet Kaur, et al. (+13)
25 [GO] 2024―May―23 Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era Bikash Medhi, Niraj Niraj, SoniaShinde Mahajan, Ajay Prakash, Phulen Sarma
26 [GO] 2024―Apr―30 Neutralization antibody titer and change in 50% protection after the third dose of the COVID-19 vaccine Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
27 [GO] 2024―Mar―08 Expected usefulness of the third dose of COVID-19 vaccine for adolescents living with underlying HIV infection Sora Yasri, Viroj Wiwanitkit
28 [GO] 2024―Mar―08 Reduction of COVID-19 vaccine-induced neutralizing antibody and changing of molecular epidemiology pattern of omicron SARS-CoV-2 subvariant: Observed interrelationship Beuy Joob, Pathum Sookaromdee, Viroj Wiwanitkit
29 [GO] 2023―Aug―07 Concurrent administration of COVID-19 vaccine and seasonal influenza vaccine: No increased estimated vaccine-related mortality rate Pathum Sookaromdee, Viroj Wiwanitkit
30 [GO] 2023―Aug―07 Kratom (Mitragyna speciosa) and COVID-19: How about the current evidence? Amnuay Kleebayoon, Viroj Wiwanitkit
31 [GO] 2022―Mar―29 Aging, VO2 max, entropy, and COVID-19 Michael Spedding, Robin Marvaud, Adrien Marck, Quentin Delarochelambert, JeanFrancois Toussaint
32 [GO] 2022―Mar―29 An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies Suparna Chatterjee, Shouvik Choudhury, Debaleena Das
33 [GO] 2021―Dec―30 Chemoprophylaxis against COVID-19 among health-care workers using Ivermectin in low- and middle-income countries: A systematic review and meta-analysis TaoreedAdegoke Azeez, Sulaiman Lakoh, AdedapoAdegboyega Adeleke, OluwanifemiTolulase Balogun, BabatundeJohn Olanipekun, FiyinfoluwaIbukun Olusola
34 [GO] 2021―Dec―30 COVID-19-associated rhino-orbital-cerebral mucormycosis: A systematic review, meta-analysis, and meta-regression analysis Bikash Medhi, Anusuya Bhattacharyya, Phulen Sarma, Hardeep Kaur, Subodh Kumar, Jaimini Bhattacharyya, et al. (+7)
35 [GO] 2021―Dec―30 Heparin-induced hyponatremia in COVID-19: A latent culprit! Pooja Singh, Rajesh Panda, Saiteja Kodamanchili, Abhijeet Anand
36 [GO] 2021―May―26 Modified drug regimen for ophthalmic anesthesia during COVID-19 pandemic: Revisiting pharmacological concepts Bharat Gurnani, Kirandeep Kaur
37 [GO] 2021―Apr―28 Indian contribution toward biomedical research and development in COVID-19: A systematic review Bikash Medhi, Hardeep Kaur, Manpreet Kaur, Anusuya Bhattacharyya, Manisha Prajapat, Prasad Thota, et al. (+6)
38 [GO] 2021―Apr―28 Implication of nanotechnology-based approaches to combat SARS-CoV-2 infection Mohsen Salmanpour, Mana Heidari, Ali-Mohammad Tamaddon
39 [GO] 2021―Feb―18 Convergence of divergent approaches to control COVID-19 RameshR Bhonde, Shivani Desai, ShivaniR Sainani, KetkiR Rode
40 [GO] 2021―Feb―18 Regulatory approval for COVID-19 across the globe Bikash Medhi, Vidya Mahalmani, T Pugazhenthan, Niti Mittal, ShobanBabu Varthya
41 [GO] 2021―Feb―18 Efficacy and safety of steroid therapy in COVID-19: A rapid systematic review and Meta-analysis Bikash Medhi, Phulen Sarma, Anusuya Bhattacharyya, Hardeep Kaur, Manisha Prajapat, Ajay Prakash, et al. (+10)
42 [GO] 2021―Feb―18 Antiviral effect of amiodarone and its possible role in COVID-19: An appraisal ChandraKr Das, Snehal Lonare, Mythili Hazarika
43 [GO] 2020―Dec―05 Novel therapeutic approaches toward Hantaan virus and its clinical features’ similarity with COVID-19 Bikash Medhi, Harvinder Singh, Harpinder Kaur
44 [GO] 2020―Dec―05 Changing drug regimen during COVID-19 pandemic lockdown: An experience from a Tertiary Eye Care Hospital as a cornea specialist Bharat Gurnani, Kirandeep Kaur
45 [GO] 2020―Dec―05 Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients Bikash Medhi, Ajay Prakash, Harvinder Singh, Hardeep Kaur, Ankita Semwal, Phulen Sarma, et al. (+2)
46 [GO] 2020―Dec―05 Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times? Francesco Ferrara, RaffaeleLa Porta, Priscilla Santilli, Vilma D'Aiuto, Antonio Vitiello
47 [GO] 2020―Aug―04 Indian perspective of remdesivir: A promising COVID-19 drug YogendraKumar Gupta, Devendra Singh, Himika Wasan, Apoorva Mathur
48 [GO] 2020―Aug―04 Sofosbuvir for COVID-19 infection: A potential candidate Rohit Gupta, Puneet Dhamija
49 [GO] 2020―Aug―04 Psychiatric implications of the use of hydroxychloroquine in COVID-19 patients Sandeep Grover, Seema Rani, Aseem Mehra, Swapnajeet Sahoo
50 [GO] 2020―Jun―02 COVID-19 pandemic: A review based on current evidence Bikash Medhi, VidyaM Mahalmani, Dhruv Mahendru, Ankita Semwal, Sukhmeet Kaur, Harpinder Kaur, et al. (+2)
51 [GO] 2020―Jun―02 Coronavirus Disease-2019 Pandemic: Hopes Ride High on Targeting Known Drugs against Unkown Bikash Medhi, VidyaM Mahalmani, Dhruv Mahendru, Phulen Sarma, Ajay Prakash
52 [GO] 2020―Mar―09 Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach Bikash Medhi, Phulen Sarma, Manisha Prajapat, Pramod Avti, Hardeep Kaur, Subodh Kumar
 [1] 

52 Results       Page 1


[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.005 sec